The Use of Weighted Z-Tests in Medical Research

ABSTRACT Traditionally the un-weighted Z-tests, which follow the one-patient-one-vote principle, are standard for comparisons of treatment effects. We discuss two types of weighted Z-tests in this manuscript to incorporate data collected in two (or more) stages or in two (or more) regions. We use the type A weighted Z-test to exemplify the variance spending approach in the first part of this manuscript. This approach has been applied to sample size re-estimation. In the second part of the manuscript, we introduce the type B weighted Z-tests and apply them to the design of bridging studies. The weights in the type A weighted Z-tests are pre-determined, independent of the prior observed data, and controls alpha at the desired level. To the contrary, the weights in the type B weighted Z-tests may depend on the prior observed data; and the type I error rate for the bridging study is usually inflated to a level higher than that of a full-scale study. The choice of the weights provides a simple statistical framework for communication between the regulatory agency and the sponsor. The negotiation process may involve practical constrains and some characteristics of prior studies.

[1]  L A Moyé,et al.  The cardiac arrhythmia suppression trial. Casting suppression in a different light. , 1995, Circulation.

[2]  L D Fisher,et al.  Self-designing clinical trials. , 1998, Statistics in medicine.

[3]  H. M. James Hung,et al.  Estimation and Confidence Intervals after Adjusting the Maximum Information , 2003 .

[4]  D. DeMets,et al.  Increasing the sample size when the unblinded interim result is promising , 2004, Statistics in medicine.

[5]  Michael A Proschan,et al.  Practical midcourse sample size modification in clinical trials. , 2003, Controlled clinical trials.

[6]  L. J. Wei,et al.  The Randomized Play-the-Winner Rule in Medical Trials , 1978 .

[7]  K K Lan,et al.  The B-value: a tool for monitoring data. , 1988, Biometrics.

[8]  Sue-Jane Wang,et al.  Adaptive Statistical Analysis Following Sample Size Modification Based on Interim Review of Effect Size , 2005, Journal of biopharmaceutical statistics.

[9]  L Fisher,et al.  Statistical Inference for Self‐Designing Clinical Trials with a One‐Sided Hypothesis , 1999, Biometrics.

[10]  Sue-Jane Wang,et al.  Modification of Sample Size in Group Sequential Clinical Trials , 1999, Biometrics.

[11]  J. Wittes,et al.  The role of internal pilot studies in increasing the efficiency of clinical trials. , 1990, Statistics in medicine.

[12]  K. K. Lan,et al.  FLEXIBLE INTERIM ANALYSIS METHOD FOR SAMPLE SIZE RE-ESTIMATION AND EARLY STOPPING: A CONDITIONAL POWER APPROACH , 2001 .

[13]  K. K. Lan,et al.  SAMPLE SIZE RE-ESTIMATION FOR BINARY DATA VIA CONDITIONAL POWER , 2002 .

[14]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.

[15]  Shein-Chung Chow,et al.  ASSESSING SENSITIVITY AND SIMILARITY IN BRIDGING STUDIES , 2002, Journal of biopharmaceutical statistics.

[16]  D. Zucker,et al.  Sequential monitoring of clinical trials: the role of information and Brownian motion. , 1993, Statistics in medicine.

[17]  Robert Lemery,et al.  Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. , 1992, The New England journal of medicine.

[18]  J. Cui,et al.  Nonparametric Estimation of a Delay Distribution Based on Left‐Censored and Right‐Truncated Data , 1999, Biometrics.

[19]  W. Shih,et al.  Clinical trials for drug registrations in Asian-Pacific countries: proposal for a new paradigm from a statistical perspective. , 2001, Controlled clinical trials.

[20]  Michael A. Proschan,et al.  A Unified Theory of Two-Stage Adaptive Designs , 2002 .

[21]  Sue-Jane Wang,et al.  Adaptive Statistical Inference Following Sample Size Modification Based on Interim Review of Effect Size * , 2002 .

[22]  W. Rogers,et al.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. , 1989, The New England journal of medicine.